[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"VA Connecticut Healthcare System\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100442493","phase-2-donepezil-and-cognitive-training-for-alcohol-use-disorder-aud-100442493",false,"NCT05042102","Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)","The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder","Inclusion criteria:\n\n1. Males and females 18-80 years of age\n2. Fluency in English and a 6th grade or higher reading level\n3. Meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a current alcohol use disorder (subjects should have a primary alcohol use disorder \\[AUD\\] diagnosis, but may have concurrent occasional use of other substances)\n4. Last alcohol use and at least one heavy drinking day within the past 30 days\n5. Willingness to attend follow-up assessments at 13 weeks\n6. Willingness to submit to Urine Toxicology screenings\n\nExclusion criteria:\n\n1. Lifetime diagnosis of a psychotic disorder, not induced by drug use\n2. Current treatment with opioids or benzodiazepines, which may affect new learning\n3. Involvement in a legal case that may lead to incarceration during the study period\n4. Residential plans that would interfere with participation\n5. Medical illness that may significantly compromise cognition (e.g., Parkinson's, Alzheimer's, Huntington's chorea, moderate or greater TBI)\n6. An uncorrected sensory impairment (hearing or sight) that would seriously interfere with cognitive training\n7. Pre-morbid intelligence quotient (IQ) estimate below 70\n8. Unstable housing or lack of commitment to staying within a geographic area that would make follow-up unlikely\n9. Unwillingness to provide contact information of someone who can help study staff contact the subjects in the event that study staff are unable to maintain contact directly\n10. Allergy to donepezil\n11. Unstable cardiovascular disease or unstable medical condition-clinically determined by a physician\n12. Imminent suicidal or homicidal risk\n13. Pregnant or nursing women, positive pregnancy test, or inadequate birth control methods in women of childbearing potential","ALL","18 Years","80 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of the project is to evaluate whether donepezil + cognitive remediation therapy is superior to placebo in reducing heavy drinking in patients with alcohol use disorder in a double-blind, placebo-controlled trial.",[27],"Alcohol Use Disorder","RECRUITING","2026-06-18",{"date":31,"type":32},"2026-06-23","ACTUAL",{"date":34,"type":32},"2022-08-08",{"date":36,"type":21},"2026-10-31",{"name":38,"class":39},"VA Connecticut Healthcare System","FED",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100462625","building-an-equitable-and-accessible-system-of-eating-disorder-care-for-va-dod-and-underrepresented-americans-100462625","NCT05304104","Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans","Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans With Eating Disorders (EASED Study)","EASED","Inclusion Criteria:\n\n* Aged 18 and older\n* Presence of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Bulimia Nervosa (BN) or Binge Eating Disorder (BED)\n* Veteran Health Administration (VHA) user\n\nExclusion Criteria:\n\n* Active psychosis or high acute risk for suicide\n* Medical or psychiatric illness, or cognitive deficits, that interfere with providing consent, completing assessments, or engaging in treatment for eating disorders\n* Pregnancy or lactation\n* Patients with suspected Anorexia or Atypical Anorexia will be excluded and referred to other VA care services",{"count":50,"type":21},144,[52],"NA","When untreated, eating disorders present with tremendous burdens to affected active duty Service members and Veterans and their families, and are very costly to the DoD and VA healthcare system. A comparative effectiveness study with state-of-the-art virtual treatment for BN and BED specifically adapted for testing with the Veteran population and other underrepresented eating disorder populations will lead to major improvements in clinical outcomes. The treatment will be integrated with VA's newest telehealth technology to profoundly enhance access to care anywhere, at any time. This trial of therapist-led and self-help CBT treatments, combined with our expert panel methods to inform VA Clinical Practice Guidelines for Eating Disorders and plans for dissemination, will accelerate the pace for the transition of results both for large-scale deployment in the VA system and for real-world impact among diverse and underrepresented eating disorder populations.",[55,56,57,58],"Binge-Eating Disorder","Bulimia Nervosa","Veterans Health","Cognitive Behavioral Therapy","2025-11-19",{"date":61,"type":32},"2025-11-25",{"date":63,"type":32},"2022-04-22",{"date":65,"type":21},"2025-12",{"name":38,"class":39},{"id":68,"slug":4,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":40},"100365920","NCT04044534","Intranasal Insulin for Posttraumatic Stress Disorder","Intranasal Insulin for Treating Posttraumatic Stress Disorder","Inclusion Criteria:\n\n* Male or female, 21-65 years old\n* Current PTSD\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Unstable medical condition, clinically determined by a physician\n* Diabetes requiring insulin or oral hypoglycemic agents\n* Moderate-severe traumatic brain injury\n* Current psychotic disorder, bipolar disorder, cognitive disorder in the past 12 months\n* Current substance use disorders (except alcohol, tobacco, or cannabis) in the past 3 months\n* Changes in doses of psychotropic medications in the past 4 weeks\n* Initiation of individual therapy or counseling in the past 4 weeks\n* Imminent suicidal or homicidal risk\n* Contraindication to Insulin\n* History of claustrophobia\n* Presence of cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a standard pre-MRI safety screening questionnaire","21 Years","65 Years",{"count":76,"type":21},20,[24],"To evaluate if intranasal insulin is effective in reducing PTSD symptoms.",[80],"PTSD",[82,80],"Intranasal insulin","2025-09-15",{"date":85,"type":32},"2025-09-16",{"date":87,"type":32},"2024-10-31",{"date":89,"type":21},"2026-05-31",{"name":38,"class":39},""]